
At Aegros, we firmly believe that access to life saving therapeutic plasma therapies should be a human right - not a privilege. Our mission is to put patients first through innovation, and we plan to do using our Australian invention, Haemafrac®. Haemafrac® separates therapeutic plasma proteins using a novel electro-separation process, delivering high purity, high-yield plasma derived medical products (PDMPs). Simultaneously, Aegros is in the final stages of completing the expansion of our pilot hyperimmune facility at Macquarie Park NSW. When operational, this plant will enable the…
Annual Revenue$50M to $100M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.